Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

Mille BaekdalSophie W NielsenCarsten P HansenJan H StorkholmGerrit van HallBolette HartmannJens J HolstTina VilsbøllAsger LundFilip K Krag Knop

Published in: Diabetes care (2023)

Empagliflozin administered the day before and immediately before a standardized liquid mixed meal test normalized fasting hyperglycemia and improved postprandial glucose tolerance in pancreatectomized patients.

Keyphrases

end stage renal disease
blood glucose
ejection fraction
newly diagnosed
chronic kidney disease
double blind
prognostic factors
insulin resistance
type diabetes
squamous cell carcinoma
patient reported outcomes
study protocol
metabolic syndrome
adipose tissue
weight loss
patient reported
phase ii study
diabetic rats